Trial Profile
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Aldesleukin; Cyclophosphamide; T cell replacement therapy
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2016 Results published in the Journal of Clinical Oncology
- 26 Aug 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 03 Aug 2012 Planned end date changed from 1 Feb 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.